Development strategy

Altevax has started the clinical development of a vaccine against brain tumours (glioblastoma), a particularly difficult cancer to treat today (3% survival rate 5 years after diagnosis). If successful, this vaccine will reach the market in 10 years.

In parallel, Altevax is seeking to build co-development or sub-license partnerships with pharmaceutical companies for other cancers than glioblastoma or in infectious diseases, especially with companies that own antigens that have been proven to work, but require a powerful adjuvant to be effective in humans.


Victor Vadaneaux, President
+ 33 7 56 96 03 40

Altevax SAS
55 Avenue Marceau - 75116 Paris
© Copyright Altevax 2018 - All Rights Reserved
Mentions légales : Site et contenus propriétés d'Altevax
Création et intégration : Justine Gélis /
Hébergeur OVH